- Home
- AUTL vs PCRX Comparison
AUTL vs PCRX Comparison
Compare AUTL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | PCRX |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.2M | 1.0B |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | AUTL | PCRX |
|---|---|---|
| Price | $1.49 | $23.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.50 | ★ $37.60 |
| AVG Volume (30 Days) | ★ 1.4M | 740.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.33 | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | $10,120,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $669.62 | $9.77 |
| Revenue Next Year | $79.78 | $9.71 |
| P/E Ratio | ★ N/A | $147.31 |
| Revenue Growth | ★ 496.00 | 26.04 |
| 52 Week Low | $1.11 | $18.80 |
| 52 Week High | $2.70 | $27.99 |
Technical Indicators
Market Signals| Indicator | AUTL | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 55.86 |
| Support Level | $1.27 | $23.10 |
| Resistance Level | $1.52 | $23.82 |
| Average True Range (ATR) | 0.11 | 1.06 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 8.33 | 81.16 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.